Cavitary tissue ablation

Abstract
The invention relates to a tissue ablation system including an ablation device having a deployable applicator head configured to be delivered to a tissue cavity and ablate marginal tissue surrounding the tissue cavity. The deployable applicator head is configured to be delivered to a tissue cavity while in a collapsed configuration and ablate marginal tissue surrounding the tissue cavity while in an expanded configuration.
Description
FIELD

The present disclosure relates generally to medical devices, and, more particularly, to a tissue ablation device having a deployable applicator head configured to be delivered to a tissue cavity and ablate marginal tissue surrounding the tissue cavity.


BACKGROUND

Cancer is a group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body. Cancer generally manifests into abnormal growths of tissue in the form of a tumor that may be localized to a particular area of a patient's body (e.g., associated with a specific body part or organ) or may be spread throughout. Tumors, both benign and malignant, are commonly treated and removed via surgical intervention, as surgery often offers the greatest chance for complete removal and cure, especially if the cancer has not spread to other parts of the body. However, in some instances, surgery alone is insufficient to adequately remove all cancerous tissue from a local environment.


For example, treatment of early stage breast cancer typically involves a combination of surgery and adjuvant irradiation. Unlike a mastectomy, a lumpectomy removes only the tumor and a small rim (area) of the normal tissue around it. Radiation therapy is given after lumpectomy in an attempt to eradicate cancer cells that may remain in the local environment around the removed tumor, so as to lower the chances of the cancer returning. However, radiation therapy as a post-operative treatment suffers various shortcomings. For example, radiation techniques can be costly and time consuming, and typically involve multiple treatments over weeks and sometimes months. Furthermore, radiation often results in unintended damage to the tissue outside the target zone. Thus, rather than affecting the likely residual tissue, typically near the original tumor location, radiation techniques often adversely affect healthy tissue, such as short and long-term complications affecting the skin, lungs, and heart. Accordingly, such risks, when combined with the burden of weeks of daily radiation, may drive some patients to choose mastectomy instead of lumpectomy. Furthermore, some women (e.g., up to thirty percent (30%)) who undergo lumpectomy stop therapy before completing the full treatment due to the drawbacks of radiation treatment. This may be especially true in rural areas, or other areas in which patients may have limited access to radiation facilities.


SUMMARY

Tumors, both benign and malignant, are commonly treated and destroyed via surgical intervention, as surgery often offers the greatest chance for complete removal and cure, especially if the cancer has not metastasized. However, after the tumor is destroyed, a hollow cavity may remain, wherein tissue surrounding this cavity and surrounding the original tumor site can still leave abnormal or potentially cancerous cells that the surgeon fails, or is unable, to excise. This surrounding tissue is commonly referred to as “margin tissue” or “marginal tissue”, and is the location within a patient where a reoccurrence of the tumor may most likely occur.


The tissue ablation system of the present disclosure can be used during an ablation procedure to destroy the thin rim of marginal tissue around the cavity in an effort to manage residual disease in the local environment that has been treated. In particular, the present disclosure is generally directed to a cavitary tissue ablation system including an ablation device to be delivered into a tissue cavity and emit non-ionizing radiation, such as radiofrequency (RF) energy, to treat the marginal tissue around the tissue cavity. The ablation device generally includes a probe having a deployable applicator member or head coupled thereto and configured to transition between a collapsed configuration, in which the applicator head can be delivered to and maneuvered within a previously formed tissue cavity (e.g., formed from tumor removal), and an expanded configuration, in which the applicator head is configured to ablate marginal tissue (via RF) immediately surrounding the site of a surgically removed tumor in order to minimize recurrence of the tumor. The tissue ablation device of the present disclosure is configured to allow surgeons, or other medical professionals, to deliver precise, measured doses of RF energy at controlled depths to the marginal tissue surrounding the cavity.


Accordingly, a tissue ablation device consistent with the present disclosure may be well suited for treating hollow body cavities, such as irregularly-shaped cavities in breast tissue created by a lumpectomy procedure. It should be noted, however, that the devices of the present disclosure are not limited to such post-surgical treatments and, as used herein, the phrase “body cavity” may include non-surgically created cavities, such as natural body cavities and passages, such as the ureter (e.g. for prostate treatment), the uterus (e.g. for uterine ablation or fibroid treatment), fallopian tubes (e.g. for sterilization), and the like. Additionally, or alternatively, tissue ablation devices of the present disclosure may be used for the ablation of marginal tissue in various parts of the body and organs (e.g., skin, lungs, liver, pancreas, etc.) and is not limited to treatment of breast cancer.


In one aspect, a tissue ablation device consistent with the present disclosure includes a dual-balloon design. For example, the tissue ablation device includes a probe including a nonconductive elongated shaft having a proximal end and a distal end and at least one lumen extending therethrough, and an expandable balloon assembly coupled to the distal end of the probe shaft. The expandable balloon assembly includes an expandable inner balloon having an inner balloon wall having an exterior surface, an interior surface and a lumen defined therein and in fluid connection with at least one lumen of the probe. The inner balloon is configured to inflate into an expanded configuration in response to delivery of a first fluid from at least one lumen of the probe into the lumen of the inner balloon.


The expandable balloon assembly further includes an expandable outer balloon surrounding the inner balloon and configured to transition to an expanded configuration in response expansion of the inner balloon. The outer balloon includes an outer balloon wall having an interior surface, an exterior surface, and a chamber defined between the interior surface of the outer balloon and the exterior surface of the inner balloon. The exterior surface of the inner balloon wall has an irregular surface defined thereon. In particular, the inner balloon wall may include a plurality of bumps, ridges, or other features arranged on an outer surface thereof configured to maintain separation between the outer surface of the inner balloon wall and the interior surface of the outer balloon wall, thereby ensuring the chamber is maintained.


The chamber defined between the inner surface of the outer balloon wall and the outer surface of the inner balloon wall is in fluid connection with at least one lumen of the probe, so as to receive a second fluid therefrom. The outer balloon wall further includes a plurality of perforations configured to allow the passage of the second fluid from the chamber to the exterior surface of the outer balloon upon delivery of the second fluid from at least one lumen of the probe into the chamber.


The ablation device further includes an electrode array comprising a plurality of conductive wires positioned within the chamber between the exterior surface of the inner balloon wall and the interior surface of the outer balloon wall. Each of the plurality of conductive wires is configured to conduct energy to be carried by the second fluid within the chamber from the interior surface to the exterior surface of the outer balloon wall for ablation of a target tissue. In particular, upon activating delivery of RF energy from the at least one conductive element, the RF energy is transmitted from the conductive element to the exterior surface of the outer balloon by way of fluid weeping from the perforations, thereby creating a virtual electrode. For example, the fluid within the chamber and weeping through the perforations on the outer balloon is a conductive fluid (e.g., saline) and thus able to carry electrical current from an active conductive element. Upon the fluid weeping through the perforations, a pool or thin film of fluid is formed on the exterior surface of the outer balloon and is configured to ablate surrounding tissue via the electrical current carried from the active conductive elements. Accordingly, ablation via RF energy is able to occur on the exterior surface of the outer balloon in a controlled manner and does not require direct contact between tissue and the conductive elements.


In some embodiments, each of the plurality of conductive wires is independent from one another. Thus, in some embodiments, each of the plurality of conductive wires, or one or more sets of a combination of conductive wires, is configured to independently receive an electrical current from an energy source and independently conduct energy. In some embodiments, each of the plurality of conductive wires is configured to conduct energy upon receipt of the electrical current, the energy including RF energy.


In some embodiments, the irregular surface defined on the exterior surface of the inner balloon wall may include a plurality of ridges. The plurality of ridges may generally extend longitudinally along the exterior surface of the inner balloon wall. The plurality of ridges may be configured to make contact with the inner surface of the outer balloon wall to maintain separation between the remaining outer surface of the inner balloon wall and the inner surface of the outer balloon wall. Each of the plurality of conductive wires may further be positioned between two adjacent ridges and one or more of the plurality of perforations of the outer balloon wall may be substantially aligned with an associated one of the plurality of conductive wires.


In some embodiments, the inner balloon may be configured to receive the first fluid from a first lumen of the probe and the outer balloon may be configured to receive the second fluid from a second lumen of the probe. The delivery of the first and second fluids to the inner and outer balloons, respectively, may be independently controllable via a controller, for example. In some embodiments, the first and second fluids are different. In other embodiments, the first and second fluids are the same. In some embodiments, at least the second fluid, which is to be delivered to the chamber and used for creating a virtual electrode in combination with the electrode array, is a conductive fluid, such as saline.


The dual-balloon design is particularly advantageous in that it does not require a syringe pump, and can be supplied with gravity-fed fluid source. In addition, the volume of fluid required within the chamber is significantly less (when compared to a single balloon design), thus less wattage is required to achieve RF ablation.


In another aspect, a tissue ablation device consistent with the present disclosure includes an expandable mesh body configured to deliver energy for tissue ablation. The tissue ablation device includes a probe comprising an elongated shaft having a proximal end and a distal end and at least one lumen providing a pathway extending from the proximal end to the distal end and an expandable mesh assembly coupled to the distal end of the probe. The mesh assembly includes a self-expanding mesh body configured to transition between a collapsed configuration and an expanded configuration. When in the collapsed configuration, the mesh body is received within the at least one lumen of the probe and when in the expanded configuration, the mesh body is deployed from the at least one lumen of the probe and expands into a predefined shape. The mesh body is comprised of an electrically conductive material and configured to conduct and deliver electrical current to target tissue when in the expanded configuration.


In some embodiments, the self-expanding mesh body includes a webbing coating one or more portions of the mesh body, wherein the web comprises a non-conductive material. The webbing is configured to block delivery of electrical current from the one or more portions of mesh body coated with the webbing.





BRIEF DESCRIPTION OF THE DRAWINGS

Features and advantages of the claimed subject matter will be apparent from the following detailed description of embodiments consistent therewith, which description should be considered with reference to the accompanying drawings, wherein:



FIG. 1 is a schematic illustration of an ablation system consistent with the present disclosure.



FIGS. 2A, 2B, and 2C are perspective views of an exemplary embodiment of a tissue ablation device including an expandable applicator head configured to transition between collapsed and expanded configurations and to ablate marginal tissue;



FIG. 3 is a perspective view, partly in section, of one embodiment of an applicator head compatible with the tissue ablation device of FIG. 1;



FIG. 4 is a perspective view of another embodiment of an applicator head compatible with the tissue ablation device of FIG. 1;



FIG. 5 is an exploded view of the applicator head of FIG. 4;



FIG. 6 is a perspective view, partly in section, of the applicator head of FIG. 4;



FIGS. 7A and 7B are sectional views of a portion of the applicator head of FIG. 6 illustrating the arrangement of components relative to one another;



FIG. 8 is a schematic illustration of the delivery of the applicator head of FIG. 3 into a tissue cavity and subsequent ablation of marginal tissue according to methods of the present disclosure;



FIG. 9 is a perspective view of another embodiment of an applicator head compatible with the tissue ablation device of FIG. 1;



FIG. 10 illustrates a method of deploying the applicator head of FIG. 9 into an expanded configuration for delivery of RF energy to a target site for ablation of marginal tissue;



FIG. 11 illustrates different embodiments of the outer surface of the applicator head of FIG. 9; and



FIG. 12 is a schematic illustration of the delivery of the applicator head of FIG. 9 into a tissue cavity and subsequent ablation of marginal tissue according to methods of the present disclosure.





For a thorough understanding of the present disclosure, reference should be made to the following detailed description, including the appended claims, in connection with the above-described drawings. Although the present disclosure is described in connection with exemplary embodiments, the disclosure is not intended to be limited to the specific forms set forth herein. It is understood that various omissions and substitutions of equivalents are contemplated as circumstances may suggest or render expedient.


DETAILED DESCRIPTION

By way of overview, the present disclosure is generally directed to a tissue ablation device having a deployable applicator head configured to be delivered into a tissue cavity and ablate marginal tissue surrounding the tissue cavity.


The tissue ablation system of the present disclosure can be used during an ablation procedure to destroy the thin rim of marginal tissue around the cavity in an effort to manage residual disease in the local environment that has been treated. In particular, the present disclosure is generally directed to a cavitary tissue ablation system including an ablation device to be delivered into a tissue cavity and emit non-ionizing radiation, such as radiofrequency (RF) energy, to treat the marginal tissue around the tissue cavity. The ablation device generally includes a probe having a deployable applicator head coupled thereto and configured to transition between a collapsed configuration, in which the applicator head can be delivered to and maneuvered within a previously formed tissue cavity (e.g., formed from tumor removal), and an expanded configuration, in which the applicator head is configured to ablate marginal tissue (via RF) immediately surrounding the site of a surgically removed tumor in order to minimize recurrence of the tumor. The tissue ablation device of the present disclosure is configured to allow surgeons, or other medical professionals, to deliver precise, measured doses of RF energy at controlled depths to the marginal tissue surrounding the cavity.


Accordingly, a tissue ablation device consistent with the present disclosure may be well suited for treating hollow body cavities, such as irregularly-shaped cavities in breast tissue created by a lumpectomy procedure. It should be noted, however, that the devices of the present disclosure are not limited to such post-surgical treatments and, as used herein, the phrase “body cavity” may include non-surgically created cavities, such as natural body cavities and passages, such as the ureter (e.g. for prostate treatment), the uterus (e.g. for uterine ablation or fibroid treatment), fallopian tubes (e.g. for sterilization), and the like. Additionally, or alternatively, tissue ablation devices of the present disclosure may be used for the ablation of marginal tissue in various parts of the body and organs (e.g., skin, lungs, liver, pancreas, etc.) and is not limited to treatment of breast cancer.



FIG. 1 is a schematic illustration of an ablation system 10 for providing ablation of marginal tissue during a tumor removal procedure in a patient 12. The ablation system 10 generally includes an ablation device 14, which includes a probe having a deployable applicator member or head 16 and an elongated catheter shaft 17 to which the deployable applicator head 16 is connected. The catheter shaft 17 may generally include a nonconductive elongated member including a fluid delivery lumen. The ablation device 14 may further be coupled to a device controller 18 and an ablation generator 20 over an electrical connection, and an irrigation pump or drip 22 over a fluid connection. As will be described in greater detail herein, the device controller 18 may be used to control the emission of energy from one or more conductive elements of the device 14 to result in ablation, as well as controlling the delivery of fluid to or from the deployable applicator head 16 so as to control the expansion and collapse of the head 16. In some cases, the device controller 18 may be housed within the ablation device 14. The ablation generator 20 may also connected to a return electrode 15 that is attached to the skin of the patient 12.


As will be described in greater detail herein, during an ablation treatment, the ablation generator 20 may generally provide RF energy (e.g., electrical energy in the radiofrequency (RF) range (e.g., 350-800 kHz)) to an electrode array of the ablation device 14, as controlled by the device controller 18. At the same time, saline may also be released from the head 16. The RF energy travels through the blood and tissue of the patient 12 to the return electrode 15 and, in the process, ablates the region(s) of tissues adjacent to portions of the electrode array that have been activated.


Turning to FIGS. 2A-2C, one embodiment of an exemplary tissue ablation device configured to ablate marginal tissue is shown. The tissue ablation devices of the present disclosure generally include a probe including a shaft 17 having a proximal end and a distal end, wherein the applicator head 16 is positioned at the distal end. In some embodiments, the shaft 17 of the probe may generally resemble a catheter and thus may further include at least one lumen for providing a pathway from the proximal end of the shaft to the distal end of the shaft and the applicator head so as to allow various components to be in fluid communication with the applicator head.


For example, in one embodiment, the applicator head includes at least one balloon configured to transition from a collapsed configuration to an expanded configuration in response to delivery of a fluid thereto. FIGS. 2A-2C illustrate the applicator head 16 transitioning from a collapsed configuration (FIG. 2A) to an expanded configuration (FIG. 2B) via delivery of a fluid to the head 16 and activated to emit energy for ablation of tissue (FIG. 2C). The at least one lumen of the shaft 17 may provide a fluid pathway from the proximal end, which may be coupled to a fluid source (i.e., irrigation pump or drip 22), and the interior volume of the balloon 16. Furthermore, as will be described in greater detail herein, the tissue ablation devices of the present disclosure further include a conductive element 19 (e.g., an electrode) positioned within the applicator head 16 and configured to deliver RF energy for the ablation of marginal tissue. Accordingly, the probe may be coupled to an RF generator 20, for example, by way of an electrical connection at the proximal end, and wiring may pass through the at least one lumen of the shaft 17 to the conductive element 19. Further, in another embodiment, the applicator head may include a self-expanding mesh-like conductive element configured to deliver RF energy upon delivery to the target site. Accordingly, one or more control wires or other components may be coupled to the mesh-like conductive element to control the retraction and expansion (e.g., via pushing and pulling) of the mesh-like conductive element from the shaft of the probe, as well as electrical wiring for electrically coupling the conductive element and RF generator, wherein such control and electrical wires may be housed within the at least one lumen of the shaft of the probe.


Accordingly, in some embodiments, the shaft 17 of the probe may be configured as a handle adapted for manual manipulation. It should be noted, however, that in other embodiments, the shaft may be configured for connection to and/or interface with a surgical robot, such as the Da Vinci® surgical robot available from Intuitive Surgical, Inc., Sunnyvale, Calif. In all cases, the shaft may be configured to be held in place by a shape lock or other deployment and suspension system of the type that is anchored to a patient bed and which holds the probe in place while the ablation or other procedure takes place, eliminating the need to a user to manually hold the device for the duration of the treatment.



FIG. 3 is a perspective view, partly in section, of one embodiment of an applicator head 100 compatible with the tissue ablation device 14 of FIG. 1. As shown, the applicator head 100 includes an inflatable balloon 102 having a plurality of perforations 104, holes, or micropores, so as to allow a fluid provided within the balloon 102, such as saline, to pass therethrough, or weep, from the balloon 102 when the balloon 102 is inflated. The perforations 104 may be sized, shaped, and/or arranged in such a pattern so as to allow a volume of fluid to pass from the interior volume of the balloon to an exterior surface of the balloon at a controlled rate so as to allow the balloon to remain inflated and maintain its shape.


As previously described, the probe further includes a conductive element 106, such as an electrode, positioned within the balloon, wherein the electrode 106 is coupled to an RF energy source 20. When in the collapsed configuration (e.g., little or no fluid within the interior volume) (shown in FIG. 2A), the balloon has a smaller size or volume than when the balloon is in the expanded configuration. Once positioned within the target site (e.g., tissue cavity), fluid may then be delivered to the balloon so as to inflate the balloon into an expanded configuration (shown in FIG. 2B), at which point, ablation of marginal tissue can occur. In particular, an operator (e.g., surgeon) may initiate delivery of RF energy from the conductive element 106 by using the controller 18, and RF energy is transmitted from the conductive element 106 to the outer surface of the balloon 102 by way of the fluid weeping from the perforations 104. Accordingly, ablation via RF energy is able to occur on the exterior surface (shown in FIG. 2C). More specifically, upon activating delivery of RF energy from the conductive element (electrode), the RF energy is transmitted from the conductive element to the outer surface of the balloon by way of the fluid weeping from the perforations, thereby creating a virtual electrode. For example, the fluid within the interior of the balloon 102 and weeping through the perforations 104 to the outer surface of the balloon 102 is a conductive fluid (e.g., saline) and thus able to carry electrical current from the active electrode 106. Accordingly, upon the fluid weeping through the perforations 104, a pool or thin film of fluid is formed on the exterior surface of the balloon 102 and is configured to ablate surrounding tissue via the electrical current carried from the active electrode 106. Accordingly, ablation via RF energy is able to occur on the exterior surface of the balloon in a controlled manner and does not require direct contact between tissue and the electrode 106.



FIG. 4 is a perspective view of another embodiment of an applicator head 200 compatible with the tissue ablation device 14 and FIG. 5 is an exploded view of the applicator head 200 of FIG. 4. As shown, the applicator head 200 includes a multiple-balloon design. For example, the applicator head 200 includes an inner balloon 202 coupled to a first fluid source via a first fluid line 24a and configured to inflate into an expanded configuration in response to the delivery of fluid (e.g., saline) thereto. The applicator head 200 further includes an outer balloon 204 surrounding the inner balloon 202 and configured to correspondingly expand or collapse in response to expansion or collapse of the inner balloon 202.


The inner balloon 202 may include an irregular outer surface 208, which may include a plurality of bumps, ridges, or other features, configured to maintain separation between the outer surface of the inner balloon 202 and an interior surface of the outer balloon 204, thereby ensuring that a chamber is maintained between the inner and outer balloons. The outer balloon 204 may be coupled to a second fluid source (or the first fluid source) via a second fluid line 24b. The outer balloon 204 may further include a plurality of perforations or holes 210 so as to allow fluid from the second fluid source to pass therethrough, or weep, from the outer balloon 204. The perforations may be sized, shaped, and/or arranged in such a pattern so as to allow a volume of fluid to pass from the chamber to an exterior surface of the outer balloon at a controlled rate.


The applicator head 200 further includes one or more conductive elements, generally resembling electrically conductive wires or tines 206, positioned within the chamber area between the inner balloon 202 and outer balloon 204. The conductive elements 206 are coupled to the RF generator 20 via an electrical line 26, and configured to conduct electrical current to be carried by the fluid within the chamber from the interior surface to the exterior surface of the outer balloon 204 for ablation of a target tissue, as will be described in greater detail herein. It should be noted that in one embodiment, the plurality of conductive wires 206 may be electrically isolated and independent from one another. This design allows for each conductive wire to receive energy in the form of electrical current from a source (e.g., RF generator) and emit RF energy in response. The system may include a device controller 18, for example, configured to selectively control the supply of electrical current to each of the conductive wires 206.



FIG. 6 is a perspective view, partly in section, of the applicator head 200 illustrating compatible with the tissue ablation device of FIG. 1. FIGS. 7A and 7B are sectional views of a portion of the applicator head 200 illustrating the arrangement of components relative to one another.


As shown in FIG. 6, the inner and outer balloons include a chamber 214 defined there between. In particular, the plurality of bumps or ridges 208 arranged on an outer surface of the inner balloon 202 are configured to maintain separation between the outer surface of the inner balloon 202 and an interior surface of the outer balloon 204, thereby ensuring the chamber 214 is maintained.


Once positioned within the target site, a first fluid may be delivered to a lumen 212 of the inner balloon 202, so as to inflate the inner balloon 202 into an expanded configuration, at which point, the outer balloon 204 further expands. A second fluid may then be delivered to the outer balloon 204 such that the second fluid flows within the chamber 214 between the inner and outer balloons 202, 204 and weeps from the outer balloon 204 via the perforations 210. Upon activating delivery of RF energy from the conductive elements 206, the RF energy is transmitted from the conductive elements 206 to the outer surface of the outer balloon 204 by way of the fluid weeping from the perforations 210, thereby creating a virtual electrode. For example, the fluid within the chamber 214 and weeping through the perforations 210 on the outer balloon 204 is a conductive fluid (e.g., saline) and thus able to carry electrical current from the active conductive elements 206. Accordingly, upon the fluid weeping through the perforations 210, a pool or thin film of fluid is formed on the exterior surface of the outer balloon 204 and is configured to ablate surrounding tissue via the electrical current carried from the active conductive elements 206. Accordingly, ablation via RF energy is able to occur on the exterior surface of the outer balloon 204 in a controlled manner and does not require direct contact between tissue and the conductive elements 206.


This embodiment is particularly advantageous in that the dual-balloon design does not require a syringe pump, and can be supplied with gravity-fed fluid source 22. In addition, the volume of fluid required within the chamber is significantly less (when compared to a single balloon design), thus less wattage is required to achieve RF ablation. Another advantage of the dual-balloon design of applicator head 200 is that it is not limited to placement within tissue cavities. Rather, when in a collapsed state, the applicator head 200 is shaped and/or sized to fit through working channels of scopes or other access devices, for example, and thus be used for ablation in a plurality of locations within the human body.


It should be further noted that the device 14 of the present disclosure, including the applicator head 200, may further be equipped with feedback capabilities. For example, while in a deflated, collapsed configuration, and prior to saline flow, the head 200 may be used for the collection of initial data (e.g., temperature and conductivity measurements (impedance measurements) from one or more of the conductive elements 206. Then, upon carrying out the ablation procedure, after certain time ablating, saline flow may be stopped (controlled via controller 18), and subsequent impedance measurements may be taken. The collection of data prior and during an ablation procedure may be processed by the controller 18 so as to provide an estimation of the state of the tissue during an RF ablation procedure, thereby providing an operator (e.g., surgeon) with an accurate indication success of the procedure.



FIG. 8 is a schematic illustration of the delivery of the applicator head 100 of FIG. 3 into a tissue cavity and subsequent ablation of marginal tissue according to methods of the present disclosure.



FIG. 9 is a perspective view of another embodiment of an applicator head compatible with the tissue ablation device of FIG. 1. FIG. 10 illustrates a method of deploying the applicator head of FIG. 9 into an expanded configuration for delivery of RF energy to a target site for ablation of marginal tissue. FIG. 11 illustrates different embodiments of the outer surface of the applicator head of FIG. 9.


As shown, the applicator head may include a silicone-webbed mesh body composed of an electrically conductive material. The mesh body may be self-expanding such that it is able to transition from a collapsed configuration, in which the mesh body is retracted within a portion of the shaft of the probe, to an expanded configuration upon deployment from the shaft of the probe. Accordingly, the mesh body may include a shape-memory alloy, or similar material, so as to allow the mesh body to transition between collapsed and expanded configurations. The mesh body is further composed of an electrically conductive material and coupled to an RF generator, such that the mesh body is configured to deliver RF energy. The mesh body may include webbing material that is applied via a dipping method, for example, such that certain portions of the coated mesh body can be exposed with a solvent, thereby enabling RF energy to be delivered through the mesh to a tissue surface when the mesh body is in the expanded configuration and in direct contact with tissue. In some embodiments, to enhance the ablation, perforations along the webbing may further allow fluid to be delivered to the outer surface of the mesh body. Since the mesh body is able to naturally expand, a fluid (e.g., saline) can be delivered via a gravity-fed bag, and no pump is needed. In some embodiments, an inner balloon may be included within the mesh body so as to reduce the volume of energized saline.



FIG. 12 is a schematic illustration of the delivery of the applicator head of FIG. 9 into a tissue cavity and subsequent ablation of marginal tissue according to methods of the present disclosure.


Accordingly, a tissue ablation devices, particularly the applicator heads described herein, may be well suited for treating hollow body cavities, such as irregularly-shaped cavities in breast tissue created by a lumpectomy procedure. The devices, systems, and methods of the present disclosure can help to ensure that all microscopic disease in the local environment has been treated. This is especially true in the treatment of tumors that have a tendency to recur.


As used in any embodiment herein, the term “controller”, “module”, “subsystem”, or the like, may refer to software, firmware and/or circuitry configured to perform any of the aforementioned operations. Software may be embodied as a software package, code, instructions, instruction sets and/or data recorded on non-transitory computer readable storage medium. Firmware may be embodied as code, instructions or instruction sets and/or data that are hard-coded (e.g., nonvolatile) in memory devices. “Circuitry”, as used in any embodiment herein, may comprise, for example, singly or in any combination, hardwired circuitry, programmable circuitry such as computer processors comprising one or more individual instruction processing cores, state machine circuitry, and/or firmware that stores instructions executed by programmable circuitry. The controller or subsystem may, collectively or individually, be embodied as circuitry that forms part of a larger system, for example, an integrated circuit (IC), system on-chip (SoC), desktop computers, laptop computers, tablet computers, servers, smart phones, etc.


Any of the operations described herein may be implemented in a system that includes one or more storage mediums having stored thereon, individually or in combination, instructions that when executed by one or more processors perform the methods. Here, the processor may include, for example, a server CPU, a mobile device CPU, and/or other programmable circuitry.


Also, it is intended that operations described herein may be distributed across a plurality of physical devices, such as processing structures at more than one different physical location. The storage medium may include any type of tangible medium, for example, any type of disk including hard disks, floppy disks, optical disks, compact disk read-only memories (CD-ROMs), compact disk rewritables (CD-RWs), and magneto-optical disks, semiconductor devices such as read-only memories (ROMs), random access memories (RAMs) such as dynamic and static RAMs, erasable programmable read-only memories (EPROMs), electrically erasable programmable read-only memories (EEPROMs), flash memories, Solid State Disks (SSDs), magnetic or optical cards, or any type of media suitable for storing electronic instructions. Other embodiments may be implemented as software modules executed by a programmable control device. The storage medium may be non-transitory.


As described herein, various embodiments may be implemented using hardware elements, software elements, or any combination thereof. Examples of hardware elements may include processors, microprocessors, circuits, circuit elements (e.g., transistors, resistors, capacitors, inductors, and so forth), integrated circuits, application specific integrated circuits (ASIC), programmable logic devices (PLD), digital signal processors (DSP), field programmable gate array (FPGA), logic gates, registers, semiconductor device, chips, microchips, chip sets, and so forth.


Reference throughout this specification to “one embodiment” or “an embodiment” means that a particular feature, structure, or characteristic described in connection with the embodiment is included in at least one embodiment. Thus, appearances of the phrases “in one embodiment” or “in an embodiment” in various places throughout this specification are not necessarily all referring to the same embodiment. Furthermore, the particular features, structures, or characteristics may be combined in any suitable manner in one or more embodiments.


The terms and expressions which have been employed herein are used as terms of description and not of limitation, and there is no intention, in the use of such terms and expressions, of excluding any equivalents of the features shown and described (or portions thereof), and it is recognized that various modifications are possible within the scope of the claims. Accordingly, the claims are intended to cover all such equivalents.

Claims
  • 1. A tissue ablation device comprising: a probe assembly comprising: a nonconductive handle including first and second fluid lines extending therethrough; andan expandable balloon assembly coupled to a distal end of the nonconductive handle and in fluid communication with the first and second fluid lines, the expandable balloon assembly comprising: an expandable inner balloon in fluid connection with the first fluid line and configured to transition from a collapsed configuration to an expanded configuration defining a spherical shape in response to delivery of a first fluid from the first fluid line, the inner balloon comprising an exterior surface including a plurality of ridges defined thereon and oriented along a longitudinal axis of the inner balloon; andan expandable outer balloon surrounding the inner balloon and comprising an interior surface in contact with each of the plurality of ridges of the exterior surface of the inner balloon such that the outer balloon is configured to correspondingly transition from a collapsed configuration to an expanded configuration in response to expansion of the inner balloon, the outer balloon comprising a plurality of chambers, each of the plurality of chambers is defined between the interior surface of the outer balloon and the exterior surface of the inner balloon and a pair of adjacent ridges of the plurality of ridges, wherein each of the plurality of chambers is in fluid connection with the second fluid line and configured to receive a second fluid therefrom, the outer balloon further comprising a plurality of perforations configured to allow passage of the second fluid from the plurality of chambers to an exterior surface of the outer balloon; andan electrode array comprising a plurality of independent conductive wires, each of the plurality of independent conductive wires including a substantially constant cross-section along its length and also including a distal end terminating within a separate respective one of the plurality of chambers.
  • 2. The tissue ablation device of claim 1, wherein each of the plurality of independent conductive wires, or one or more sets of a combination of the plurality of independent conductive wires, is configured to independently receive an electrical current from an energy source and independently conduct energy.
  • 3. The tissue ablation device of claim 1, wherein each of the plurality of independent conductive wires is substantially aligned with a respective one of the plurality of perforations of the outer balloon.
  • 4. The tissue ablation device of claim 1, wherein delivery of the first and second fluids to the inner and outer balloons, respectively, is independently controllable via a controller.
  • 5. The tissue ablation device of claim 1, wherein the inner and outer balloons comprise a non-conductive material.
CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. Non-Provisional application Ser. No. 15/142,616, filed Apr. 29, 2016, which application claims the benefit of, and priority to, U.S. Provisional Application Ser. No. 62/154,377, filed Apr. 29, 2015, the content of each of which is hereby incorporated by reference herein in its entirety.

US Referenced Citations (171)
Number Name Date Kind
4699147 Chilson et al. Oct 1987 A
4976711 Parins et al. Dec 1990 A
4979948 Geddes et al. Dec 1990 A
5045056 Behl Sep 1991 A
5100423 Fearnot Mar 1992 A
5117828 Metzger et al. Jun 1992 A
5334193 Nardella Aug 1994 A
5429605 Richling et al. Jul 1995 A
5471982 Edwards et al. Dec 1995 A
5472441 Edwards et al. Dec 1995 A
5486161 Lax et al. Jan 1996 A
5536267 Edwards et al. Jul 1996 A
5562720 Stern et al. Oct 1996 A
5657760 Ying et al. Aug 1997 A
5672153 Lax et al. Sep 1997 A
5672173 Gough et al. Sep 1997 A
5672174 Gough et al. Sep 1997 A
5683384 Gough et al. Nov 1997 A
5713942 Stern et al. Feb 1998 A
5728143 Gough et al. Mar 1998 A
5772590 Webster, Jr. Jun 1998 A
5782827 Gough et al. Jul 1998 A
5827276 LeVeen et al. Oct 1998 A
5840076 Swanson et al. Nov 1998 A
5846239 Swanson et al. Dec 1998 A
5855576 LeVeen et al. Jan 1999 A
5863290 Gough et al. Jan 1999 A
5868736 Swanson et al. Feb 1999 A
5868776 Wright Feb 1999 A
5871483 Jackson et al. Feb 1999 A
5888198 Eggers et al. Mar 1999 A
5891136 McGee et al. Apr 1999 A
5893847 Kordis Apr 1999 A
5913855 Gough et al. Jun 1999 A
5928229 Gough et al. Jul 1999 A
5935123 Edwards et al. Aug 1999 A
5961513 Swanson et al. Oct 1999 A
5980517 Gough Nov 1999 A
6009877 Edwards Jan 2000 A
6032077 Pomeranz Feb 2000 A
6036689 Tu Mar 2000 A
6053913 Tu et al. Apr 2000 A
6053937 Edwards et al. Apr 2000 A
6063081 Mulier et al. May 2000 A
6071278 Panescu et al. Jun 2000 A
6071280 Edwards et al. Jun 2000 A
6099526 Whayne et al. Aug 2000 A
6112123 Kelleher et al. Aug 2000 A
6123718 Tu et al. Sep 2000 A
6142993 Whayne et al. Nov 2000 A
6221071 Sherry et al. Apr 2001 B1
6241666 Pomeranz et al. Jun 2001 B1
6251109 Hassett et al. Jun 2001 B1
6258087 Edwards et al. Jul 2001 B1
6309352 Oraevsky et al. Oct 2001 B1
6312408 Eggers et al. Nov 2001 B1
6312429 Burbank et al. Nov 2001 B1
6358248 Mulier et al. Mar 2002 B1
6379353 Nichols Apr 2002 B1
6409722 Hoey et al. Jun 2002 B1
6425877 Edwards Jul 2002 B1
6454766 Swanson et al. Sep 2002 B1
6491710 Satake Dec 2002 B2
6494902 Hoey et al. Dec 2002 B2
6503247 Swartz et al. Jan 2003 B2
6522930 Schaer et al. Feb 2003 B1
6537248 Mulier et al. Mar 2003 B2
6537272 Christopherson et al. Mar 2003 B2
6544262 Fleischman Apr 2003 B2
6551310 Ganz et al. Apr 2003 B1
6585732 Mulier et al. Jul 2003 B2
6623481 Garbagnati et al. Sep 2003 B1
6638275 McGaffigan et al. Oct 2003 B1
6648883 Francischelli et al. Nov 2003 B2
6692466 Chow et al. Feb 2004 B1
6736810 Hoey et al. May 2004 B2
6736811 Panescu et al. May 2004 B2
6743226 Cosman et al. Jun 2004 B2
6764487 Mulier et al. Jul 2004 B2
6780183 Jimenez, Jr. et al. Aug 2004 B2
6805131 Kordis Oct 2004 B2
6826421 Beatty et al. Nov 2004 B1
6849073 Hoey et al. Feb 2005 B2
6872206 Edwards et al. Mar 2005 B2
6878149 Gatto Apr 2005 B2
6955641 Lubock Oct 2005 B2
6978788 Klimberg et al. Dec 2005 B2
6984232 Vanney et al. Jan 2006 B2
7104989 Skarda Sep 2006 B2
7150745 Stern et al. Dec 2006 B2
7156845 Mulier et al. Jan 2007 B2
7169144 Hoey et al. Jan 2007 B2
7247155 Hoey et al. Jul 2007 B2
7276061 Schaer et al. Oct 2007 B2
7306593 Keidar et al. Dec 2007 B2
7326208 Vanney et al. Feb 2008 B2
7344535 Stern et al. Mar 2008 B2
7364579 Mulier et al. Apr 2008 B2
7367972 Francischelli et al. May 2008 B2
7371231 Rioux et al. May 2008 B2
7399299 Daniel et al. Jul 2008 B2
7416552 Paul et al. Aug 2008 B2
7419489 Vanney et al. Sep 2008 B2
7556628 Utley et al. Jul 2009 B2
7632268 Edwards et al. Dec 2009 B2
7717909 Strul et al. May 2010 B2
7769432 Klimberg et al. Aug 2010 B2
7776034 Kampa Aug 2010 B2
7828793 Thompson et al. Nov 2010 B2
7862498 Nguyen et al. Jan 2011 B2
7879030 Paul et al. Feb 2011 B2
7942873 Kwan et al. May 2011 B2
7959628 Schaer et al. Jun 2011 B2
7959631 DiCarlo Jun 2011 B2
8034022 Boatman Oct 2011 B2
8043289 Behl et al. Oct 2011 B2
8048069 Skwarek et al. Nov 2011 B2
8114071 Woloszko et al. Feb 2012 B2
8224416 de la Rama et al. Jul 2012 B2
8303584 Burdio Pinilla et al. Nov 2012 B2
8388573 Cox Mar 2013 B1
8398624 Rioux et al. Mar 2013 B2
8409193 Young et al. Apr 2013 B2
8444638 Woloszko et al. May 2013 B2
8465484 Davalos et al. Jun 2013 B2
8465486 Danek et al. Jun 2013 B2
8588886 de la Rama et al. Nov 2013 B2
8591461 Boatman Nov 2013 B2
8617158 Garabedian et al. Dec 2013 B2
8647339 Satake Feb 2014 B2
8657814 Werneth et al. Feb 2014 B2
8734439 Gough et al. May 2014 B2
8814855 DiCarlo et al. Aug 2014 B2
8834461 Werneth et al. Sep 2014 B2
8979841 Kunis et al. Mar 2015 B2
9078665 Moss et al. Jul 2015 B2
20010031941 Edwards et al. Oct 2001 A1
20020026186 Woloszko et al. Feb 2002 A1
20020087208 Koblish et al. Jul 2002 A1
20020095152 Ciarrocca et al. Jul 2002 A1
20020115992 Utley et al. Aug 2002 A1
20030036680 Black Feb 2003 A1
20030225403 Woloszko et al. Dec 2003 A1
20040087936 Stern et al. May 2004 A1
20050154386 West et al. Jul 2005 A1
20060259027 Kwan et al. Nov 2006 A1
20070083195 Werneth et al. Apr 2007 A1
20080004534 Gelbart et al. Jan 2008 A1
20080103494 Rioux et al. May 2008 A1
20090171340 Young Jul 2009 A1
20090292177 Eggers et al. Nov 2009 A1
20090299355 Bencini Dec 2009 A1
20100114087 Edwards et al. May 2010 A1
20110172485 Lubock Jul 2011 A1
20110257646 Utley et al. Oct 2011 A1
20120029510 Haverkost Feb 2012 A1
20120109250 Cates et al. May 2012 A1
20130085493 Bloom et al. Apr 2013 A1
20130158536 Bloom Jun 2013 A1
20130172870 Germain et al. Jul 2013 A1
20130184702 Neal, II et al. Jul 2013 A1
20130253506 Rioux Sep 2013 A1
20140018794 Anderson Jan 2014 A1
20140031810 Mahvi et al. Jan 2014 A1
20140276748 Ku et al. Sep 2014 A1
20150141982 Lee May 2015 A1
20160113708 Moss et al. Apr 2016 A1
20160184008 Papaioannou et al. Jun 2016 A1
20160317221 Rioux Nov 2016 A1
20170000559 Rioux et al. Jan 2017 A1
20170119454 Rioux et al. May 2017 A1
Foreign Referenced Citations (11)
Number Date Country
2610858 Apr 2004 CN
102010032932 Feb 2012 DE
0777445 Jun 1999 EP
2942023 Feb 2016 EP
3009735 Feb 2000 JP
9510326 Apr 1995 WO
9942047 Aug 1999 WO
0051683 Sep 2000 WO
2012015722 Feb 2012 WO
2014022379 Feb 2014 WO
2015142674 Sep 2015 WO
Non-Patent Literature Citations (16)
Entry
International Search Report and Written Opinion of the International Searching Authority dated Jun. 11, 2017 for International Application No. PCT/US2017/019398 (27 Pages).
Extended European Search Report dated Jun. 10, 2016 for European Application No. 13825361.2 (13 Pages).
International Search Report and Written Opinion of the International Searching Authority dated Aug. 22, 2016 for International Application No. PCT/US2016/030081 (11 Pages).
International Search Report and Written Opinion of the International Searching Authority dated Aug. 5, 2015 for International Application No. PCT/US2015/020596 (13 Pages).
International Search Report and Written Opinion of the International Searching Authority dated Feb. 2, 2017 for International Application No. PCT/US2016/059345 (10 Pages).
International Search Report and Written Opinion of the International Searching Authority dated May 16, 2017 for International Application No. PCT/US2017/015582 (11 pages).
International Search Report and Written Opinion of the International Searching Authority dated May 16, 2017 for International Application No. PCT/US2017/015584 (11 pages).
International Search Report and Written Opinion of the International Searching Authority dated Nov. 29, 2013 for International Application No. PCT/US2013/052703 (11 Pages).
“Aquamantys System” Product Brochure, Medtronic, 2014 (12 Pages).
“Starburst Talon” Specifications Brochure, Angiodynamics, 2013 (2 Pages).
Medtronic, “Aquamantys Bipolar Sealers.” Electrosurgical Products, Jun. 2017. Retrieved Jul. 21, 2017. <http://www.medtronic.com/us-en/healthcare-professionals/products/general-surgery/electrosurgical/aquamantys-bipolar-sealers.html> (11 Pages).
Non-Final Office Action dated Aug. 11, 2017 for U.S. Appl. No. 15/337,334 (11 Pages).
Response to Non-Final Office Action Filed Sep. 20, 2017 for U.S. Appl. No. 15/337,334 (6 Pages).
Non-Final Office Action dated Aug. 11, 2017 for U.S. Appl. No. 15/624,327 (11 Pages).
Response to Non-Final Office Action Filed Sep. 19, 2017 for U.S. Appl. No. 15/624,327 (8 Pages).
International Search Report and Written Opinion of the International Searching Authority dated Oct. 19, 2017 for International Application No. PCT/US2017/041501 (63 Pages).
Related Publications (1)
Number Date Country
20170281271 A1 Oct 2017 US
Provisional Applications (1)
Number Date Country
62154377 Apr 2015 US
Continuations (1)
Number Date Country
Parent 15142616 Apr 2016 US
Child 15624230 US